The role of meldonium and individualized physical activities in the treatment of patients with heart failure
Key facts
- Where
- Riga, LettországSee the site
- Phase
- 4. fázis
Where in Lettország
- Pauls Stradins Clinical University HospitalRiga, LettországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pauls Stradins Clinical University Hospital
- Trial code
- EU 2023-509804-14-00
- Record updated
- 2024. március 27.
- Original description
To evaluate effectiveness of meldonium and individualised physical activity recommendations in patients with heart failure with preserved ejection fraction.Read full original descriptionShow less
To evaluate effectiveness of meldonium and individualised physical activity recommendations in patients with heart failure with preserved ejection fraction.
Inclusion: Chronic heart failure II - III functional class NYHA (The New York Heart Association); In transthoracic echocardiography calculated left ventricle ejection fraction >50 un LAVI >34 ml/m2; Patient receives optimal medical therapy for at least 3 months; Coronary angiography or computed coronary angiography has been done to rule out obstructive coronary artery disease; Patients ≥18 years.
Exclusion: Allergic reaction to meldonium; Congenital heart diseases; Moderate to severe cardiac valve diseases; Iron deficiency anemia (men Hb < 13 g/dL, women Hb <12 g/dl un serum ferritin levels < 30ng/ml or transferrin saturation ≤19 %); Patient is involved in other trial; Severe kindey or liver disfunction; Pregnancy/breastfeeding women; Patient uses digoxin, trimetazidine, ranolazine, meldonium, ivabradine; Patient underwent coronary revascularisation within 3 months.